The Biggest Risk To ABA Might Be Perception: Autism Therapy Under the Microscope with Chris Larson (Part I)
59 minAudio
Send us Fan Mail ABA on Tap is proud to present Chris Larson (Part 1 of 2): Autism therapy sits at the intersection of healthcare, politics, and money, and that collision is getting louder. Mike and Dan talk with healthcare journalist Chris Larson from Behavioral Health Business about why ABA has become an easy target for skepticism, how federal narratives can trickle down into real-world payer behavior, and what parts of the backlash are cultural versus policy-driven. We also get concrete about the mechanics that shape a providerโs survival. Chris explains why Medicaid acts like the pace-setting car for reimbursement and utilization rules, how state Medicaid programs can rapidly tighten oversight, and why changes like fixed fee schedules, accreditation expectations, and hour caps can reshape access. Even if you mostly serve commercial members, you still feel Medicaid and Medicare influence through benchmarks like daily limits and authorization standards. Then we tap into the private equity debate with fewer slogans and more operations. Why did some investor-backed ABA roll-ups collapse while others kept growing? We break down thin margins, reimbursement delays, scaling problems, and the shortage of executives who truly understand the subtleties of autism therapy delivery. If youโre a BCBA, clinic leader, or founder trying to build ethical growth in a volatile market, this conversation gives you a clearer map of the terrain. Subscribe, share this with a colleague, and leave a review with your biggest question about where ABA goes next. Tune in, Drink Up and ALWAYS ANALYZE RESPONSIBLY. Support the show ๐ฅ Enjoyed this episode? Donโt forget to subscribe, rate, and review on your favorite podcast platform! ๐ข Connect with Us: ๐ Website: https://abaontap.com ๐ง TikTok: https://www.tiktok.com/@aba.on.tap.podcast ๐ธ Instagram: https://www.instagram.com/abaontap/ ๐ฅ YouTube: https://www.youtube.com/@ABAonTap ๐ผ LinkedIn: https://www.linkedin.com/company/aba-on-tap ๐ก Support the Show: โ Love what we do? Buy us a virtual drink! Support ABA on Tap ๐๏ธ Interested in sponsoring? Partner with us ๐ Join the ABA on Tap Community! Stay updated on the latest episodes, live events, and exclusive content. ๐ง Analyze Responsibly & Keep the Conversation Going! ๐ป
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_01Welcome to ABA on tech. A mic review with Dan Lowry. So without further ado, sit back, relax, and always analyze responsibly.
SPEAKER_01All right, all right. And welcome back to yet another installment of ABA on tap. I am your ever-grateful co-host, Mike Rubio. And sitting in front of me today, not to my right as usual, because it's a special occasion today on so many levels. Mr. Dan Lowry, how are you doing?
SPEAKER_00I'm great. So excited to be here. We're making an accommodation, but we're doing this for a really, really interesting, exciting podcast.
SPEAKER_01For really good reasons. Really good reasons. Yes. We were talking about non-BCBAs, non-clinicians we've had on the show as guests. Not a long list. And then today a real treat, I would say. Somebody who can probably answer a lot of the questions, say about funding sources that we've had here. I don't know that he'll get to today or that he can per se based on his work, but I'm sure he has the information. He gets to talk to all those people that we've wanted to talk to outside of those audits and goal of our treatment plan reviews, and then it's going to illuminate us on a whole lot of topics as related to us as new business owners on a new venture and learn a whole lot about that.
SPEAKER_00Yeah, we love to uh just geek out, and a lot of times it's geeking out in the uh the ABA space, and this will be that as well. But this is a little bit of you know change, and we're it's uh we're just excited to be able to geek out today.
SPEAKER_01So today's guest, a prominent journalist in the field, well, in his own right, and then gets to specialize in matters in and around ABA business and clinical practice. So without further ado, today's guest is Chris Larson.
unknownMr.
SPEAKER_01Chris Larson, sir, thank you for sticking with us. This is a long time coming. We had to work really hard together to make this happen. And uh, you're doing so here with a whole bunch of other things that you have to take care of in your background, but choosing to give us a couple of hours of your time. We can't thank you enough. How are you doing today?
SPEAKER_03Hey, I'm doing great and so incredibly grateful to have the chance to be here. And I know part of the accommodation is go to the recording schedule. And as someone who works in media full-time, I can tell you just how important it is to get your schedule going, find something that works, and then stick to it. So to be part of your guys' show, you know, in a off kind of an off-recording day, I rarely recognize like how how big of a deal that is. And I'm so grateful to be a part of it.
SPEAKER_01Well, we we appreciate you right back, sir. Super excited to learn from you today. Given the extensive amount of writing you've done about our fields, I can only imagine all the different tangents uh we're gonna enjoy going on together. We want to put you through the same treatment. You you get to be, I'm glad you're excited to be on the show. We are humbled by that, but we want to hear your origin story as a journalist, and then maybe take us right to the point where more specifically you've been writing about applied behavior analysis, business venture practice, and all those things.
SPEAKER_01So I'll pass it right to you, sir.
SPEAKER_03Alrighty. Well, my background is actually really straightforward. And as you said, like in delete and into the intro, I'm not, I want to make a couple of disclaimers that for what I do know, there's a lot of things that I cannot know. I'm not a parent of a child with someone with autism. I'm not a clinician. And my my experience and my knowledge, frankly, pales because it is a bit ephemeral, because it doesn't come with the lived experience that so many of the people that come onto those podcasts are able to share with to share with share with listeners. But I'll I'll do my I I do my very best.
SPEAKER_03And that's kind of the long and short of like what I do with my life and my career is just do do your very best and do your very best all the time. And that ethos is kind of where I and how I ended up here in journalism. I went to college thinking that I was going to be a doctor, I was going to do cardiothoracic surgery, but then my small town public school education came back to bite me in the butt. And that that what that translates to is like me failing uh chemistry and physics multiple times and then realizing that I could either grind through like seven years of undergraduate or I could pivot to a natural strength and get on with my life.
SPEAKER_03And you know, I I went I started college circa like I want to say like 2011, 2012. So, you know, just a couple years after the bottom fell out in in 2008. So I was hearing about like friends and older brothers and other older sisters who were going to college getting stuck there too long and leaving with a whole lot of debt, and I didn't want to do that. So strategically speaking, I needed to do something different with my life and career. And there's a lot of thinking that went into it, and it all came back to just what can you do your very best in and can you do it every day? And that led me to journalism.
SPEAKER_03Felt like I found a calling, felt like I found the thing that was for me. And from then on, I've just been writing in every every capacity that I could, really focusing on news and shying just very slightly away from a lot of the kind of like bigger picture stuff that's more the more articulates the like the vibe, the culture. I wanted I started off trying to cover politics in Salt Lake City with through the university that I was going to as a program where I get to kind of stalk the halls and for a couple of months and try to talk to lawmakers and their staff.
SPEAKER_03I got a job in Louisville, Kentucky, writing about local healthcare. Started that job in December of 2016, and that was my entree into the world of writing about healthcare. And in the context of my work today, I honestly had no idea that behavioral health was its own thriving, growing, but nonetheless, and I think it's evidenced by the experience, kind of siloed segment of healthcare. I was writing a lot about hospitals, about nursing homes, about doctors' offices, independent practices, you know, dental service organizations. And the only time that writing about the behavioral health industry would come up was in the context of the impacts of the opioid epidemic, right?
SPEAKER_03So Kentucky Appalachia has taken a really, really heavy hit over the course of the last 25 years on how opioids as a as prescriptions were handled, or I guess rather mishandled by all kinds of powerful entities. And but even then it didn't the the scale, the significance of the industry didn't really dawn on me until the previous owner of Behavioral Health Business reached out to me to apply to work here. And it was a revelatory experience to realize that there's this whole other world to healthcare that unless you have a very deep and personal connection to it, you probably don't know that it exists.
SPEAKER_03So, right, if you don't if you yourself or a dear family member hasn't gone through addiction, hasn't had a serious mental mental health episode, if you don't have a child, cousin, brother, sister, dad who's on the spectrum, whatever it is, you don't know that this world exists. And that was me until I got the chance to start working here. So how did I end up writing a lot about autism? I just I there were there were a lot of news developments in the summer of 22 and the summer of 23.
SPEAKER_03This was around the time that Center for Autism and Related Disorder started to experience a lot of financial trouble. And I believe they filed for bankruptcy in 23. But the financial troubles of what at that time was kind of the bellwether for investor-backed, nationally scaled ABA providers, since that was going poorly, there was a lot of worry and a lot of attention being paid for paid on that specifically. And it was really kind of just by circumstance that I decided to take that, and then since I had already done it before and everybody at BHB is new, we've only been around for gosh, I see since the fall of 2019 is when we started.
SPEAKER_03Everyone else is really new and nobody had an expertise there. So I just decided that I would do my very best with this story. And then since I had done my very best with that story, uh, if there was another story about the autism therapy industry that came up, I would I took that one, and then before you know it, um Behavior Health Business is now the the grateful steward of the Autism Investor Summit. We've expanded that to Autism Investor Summit East as well. We had a we do have a dedicated autism business news brand. So like that's our newsletter that goes out every month where we consolidate the top five stories of that we cover there and has led us to take a very special focus on this really important industry.
SPEAKER_03So that's my backstory.
SPEAKER_01Oh wow, man. Incredible, incredible. I don't even know where to start in terms of learn just learning more about the opioid crisis. I know that we don't we don't tend to cover that particular news story here. We we're more autism related and looking at how behavior analysis applies beyond that, which is maybe something that that uh you've come across in terms of expanded pediatric practice. But we certainly appreciate just that quick synopsis you gave in terms of now our experiences as clinicians and thinking about those events and what you know some of those things now started doing to us in practice in terms of a couple of those moments of like between these things happening financially to big providers like Card and then now the backlash from the neurodivergent community, that was you know a couple tough years for us as well, in terms of are we going to exist?
SPEAKER_01Is this going away? You know, throw in some other multi-level marketing situations out there that are giving parents a lot of hope, and it gets a little bit scary, you know. What just maybe to get right to this, what would you say is is the grimace part of this particular field of practice, of this particular healthcare line at at this point in time? And I'm gonna keep that question very general so that we can kind of dissect it along the way, but you know, it ebbs and flows, there's a lot of opportunity, and yet if you look at you know any given sector with a recent RBT strike, with uh I want to talk about that and see what you know about that, but yeah, there's a lot of turmoil too.
SPEAKER_01This is still a very young industry and and the future seems a little bit uncertain. What would you say about that in general?
SPEAKER_03So, generally speaking, I would say yes, agree, totally agree with the premise. Very new field in terms of a field as far as we recognize it within the context of just kind of managed care healthcare in the world where there are third-party payers that try to reduce everything down to a you know CPT code and then try to pay for it according to whatever, you know, whatever standards that they have for both their their financial interests but also the interests of the members that they have. So, I mean, you guys know way better than me the principles and the practices of this field go way beyond you know the moment that we're in now.
SPEAKER_03And because of the fact that there are routes to this industry that reach back decades, I have all confidence that it's going to continue to be a meaningful and extant part of the healthcare scene. Now, what does it look like? That's an open question that you can hotly debate because frankly, nobody has a crystal ball. And you know, it's kind of up to us all in the present to try to puzzle out what we're gonna see in the future, right? But to answer your question directly, like what is like the the the grimmest line and most concerning thing that I see overall for uh this as like a as a practice, as a way that people make their living, and as opposed to something that just kind of exists in the halls of academia, it's it's probably the the the the potent skepticism on autism generally coming down from the federal government.
SPEAKER_03RFK Jr. has made it a key point of his pub public statement in his career to questions the validity, the origins of autism. Now that has a huge impact on the community. It doesn't necessarily have a big direct impact on the treatment of providers or on the system of treatment providers that exist today. So a lot of his work on trying to throw money into research to get to root causes, questionable green lighting of potential pharmaceutical routes to help alleviate certain symptoms, those don't directly necessarily my mind like attack or question or tamper with the roots.
SPEAKER_03Nonetheless, RF Canazone is a very powerful cultural figure. The federal government is the paragon of power in on the globe right now in every aspect. The United States federal government is the most powerful entity when it comes to literally any aspect of life that you want to talk about. So to have that belief, those that you know, that ethic and that skepticism exist at that level has a really powerful trickle-down effect into all these aspects that we can get into. Kind of a parallel to it, not necessarily a connection to it, but a parallel to it is a lot of the skepticism that there is for ABA as a practice as far as it's built under Medicaid.
SPEAKER_03The OIG has that has an ongoing series of investigations on the billing practices that states are establishing with their payer partners. Now, the findings don't reflect well on providers either, but this goes to show that ABA is kind of a punching bag right now and kind of a very easy, and pardon the harsh, the harsh language, but a a whipping boy for a lot of the problems that healthcare is seeing collectively because of its youth, because of its of its remarkable and frankly explosive growth, but be also because of these biases and this misunderstanding, it makes it really easy to blame.
SPEAKER_03It makes it really easy to set up as this is the problem, let's let's go, you know, harangue this, frankly, small relative to the rest of the totality of healthcare sector.
unknownYeah.
SPEAKER_01Well, and I mean to to your point there, and in all fairness, for example, with with fraud, we are new to the table, and I would argue that probably just about every other medical health treatment that's new to the table has gone through this growing pain of either seeing the potential for growth and profit so people get fraudulent, or just not knowing what the hell you're doing, and you end up doing something stupid and potentially fraudulent. So you you put together three or four really good factors there in terms of what paints a grim picture or what defines the growing pain.
SPEAKER_01So we're gonna have a lot to talk about. Mr. Dan, I'm gonna pass it to you, sir. Sure.
SPEAKER_00It's interesting that you talk about the federal government because I do remember RFK saying, was it last sept he was gonna have a cure for autism by this September or last September? I think it was last September, right?
SPEAKER_01Chris, can you help us out with that? I thought this autism thing was over, right?
SPEAKER_03Yeah, the I you you guys are right. I I can't remember exactly when it was, to be completely honest. While I did understand and I did try to process what was going on, like we would try to find we would try to know the cause of autism by now. It obviously hasn't happened. It was such a frankly ridiculous thing to say that me as like an out as an outward observer who does I do my absolute darndest to separate myself from the story from what I'm taking on and try to be as logical and as fair and as objective as possible. But even even in that mode of thinking, that was just such a ludicrous thing to say that you were going to do.
SPEAKER_03And in the context of such so many other pressing public health issues, why that? So it it's it was such a strange and unusual thing that I don't I didn't I don't give it a whole lot of brain space, so I don't know when the date was because it was so because I didn't really think too much about it.
SPEAKER_01Well, that's okay, and I think it was it it's a year away. It was last September. It was last September. So we're almost a year from that. But anyway, yeah, we're we're off. I'm I was glad you mentioned RFK. I'm glad Dan picked up on that. I think we're gonna spend a little time on because this does feed this general notion. You started out by talking about how how hard it is to know about this sector, this demographic, unless you're in it. And now the general public is getting a whole bunch of miss discs, whatever prefix you want to put before information about this.
SPEAKER_01So what's been one of my frustrations is uh talking to family members that maybe have a more conservative approach to their lifestyle, and now they're teaching me about the things that I've been doing over the past 30 years, and it's like, oh, this is really hard. Anyway, Mr. Dan.
SPEAKER_00Yeah. So I I think that that's interesting that you brought it up about the what your kind of number one cause for concern being kind of the the view from the federal government, and because that is such a powerful entity, I think something that you know I maybe sort of rest assured is is that you know, the four every four-year change and that this administration, presumably any barring any constitutional, you know, changes will be gone. And hopefully the damage control will be able to be done and there won't be a lot of you know irreparable damage being done.
SPEAKER_00So that's you know, because the government doesn't move super quickly. So I guess that's maybe that's ignorance. Maybe, you know, maybe by the time that they leave that there will be a huge difference in an opinion and public perception. What are your thoughts on that, Chris? Do you think it's uh blissful ignorance that I'm like there won't be enough damage to be done by the time that this administration leaves? Or do you think that's a legitimate, like, by the time this administration leaves, that the the landscape might look very different?
SPEAKER_03So there's there's no doubt that the landscape is going to look very different by the time the Trump administration is over. Again, what that looks like, highly open for debate. Now, the reason that I highlight the federal government is because it's frankly a really easy place to go, just because it is so powerful. We actually have seen a lot of the specific focus on autism kind of tape rough a little bit as the administration gets distracted by any number of other issues that it has to deal with. Granted, you have a huge entity that makes up just the executive branch.
SPEAKER_03You have several people and personalities that have any number of issues that'll dominate headlines over the course of any number amount of time.
SPEAKER_00Like diarrhea lettuce. So I'm actually thankful for diarrhoea lettuce to get them off of autism for a little bit.
SPEAKER_03Yeah, and that's what that's exactly what I'm talking about. And there's because of the people like that, honestly, in the federal government that are making a lot of decisions, being they themselves being really easily distracted by the shiny keys. And because, you know, naturally national media trying to follow that, they're also going to be distracted from it as well. There's just going to be like not nearly as much, I think, to talk about by the time we're done with the the Trump administration from the specifically from the federal government standpoint. Now, what's not going to go away is what the uh Trump administration on this term is probably going to be best known for in the healthcare policy world, and that's going to be the one big beautiful bill act.
SPEAKER_03That barring, again, like a very dramatic change, not only a change in the administration, and then a total change in the makeup of Congress to like try to undo or tinker or redo or add in or amend that law. We are going to see a permanent state of change for probably the next five years until the one big beautiful Bill Act's Medicaid provisions are fully realized and implemented. And of course, you know, everyone sues everything all the time, especially when it comes to federal government and state politics. So there may be questions about how Medicaid handles benefits generally, and may that that may have a trickle-down effect into autism therapy benefits as well.
SPEAKER_03But like that's not going to go away, even once the Trumps leave the White House.
SPEAKER_00So what are the biggest in the Big Beautiful Act, what are the biggest things that you see that are directly having an effect on ABA community?
SPEAKER_03So the ones that have the biggest effect are how probably the general funding provisions for Medicaid. Now, a lot of like the big issues when it comes to work requirements, they they simply don't apply to your traditional Medicaid populations. So children, pregnant, pregnant single women, things like that. So we're lucky that we're probably not going to see a lot of the strictest, most dire changes to the When Big Beautiful Bill Act actually impact autism therapy providers because of frankly how insulated children are in Medicaid and even in these changes to Medicaid.
SPEAKER_03What will be difficult, especially difficult, is what role autism therapy decide providers decide to play when it comes to the renewal process for people who have these benefits. Now, I'll have to double check this, and you know, everybody, you probably should be having these conversations anyway with your billing experts, with your RCM folks. But I do believe that the requirement to certify your eligibility twice a year might also fall to fall to children. If it doesn't, then you know it's going to be just normal sailing through through the course.
SPEAKER_03But like depending on how states approach this, and ABA spend has been absolutely wild at the state level, they might want to try to do something on their own, get exemptions to the federal laws through whatever waivers that they have to try to be as strict as possible on who can bill and who's eligible for Medicaid. But you know, again, I'll point out that that change is going to be there, is going to be there forever.
SPEAKER_00And so talking on the the federal level, I'm also seeing a lot of rumblings or more hearing a lot of rumblings on the state level about the you know the various Medicaids of the states. I think uh there was a big one in Indiana. Uh maybe they've kind of reworked some things. So, kind of what are you seeing on the state level? And is that are are you seeing that potentially having a big effect on the way that ABA is provisioned as well? Profound effect.
SPEAKER_03Speak on that. Yeah, gladly. So while the federal government has an enormous amount of impact on everybody's Lives, the part of the government that has the most intimate, the most active impact on everybody's lives is going to be the state government. This gets cranked up to 11 when we're in healthcare because of healthcare's proximity always and forever, no matter what field you're in, to the Medicaid program. Medicaid is kind of like the pace setting car for all of healthcare when it comes to reimbursement standards and how the kind of business aspect of healthcare has operated.
SPEAKER_03So what Medicaid does, you're probably going to see it all across that state because of just the importance of that it plays in the space. So I'll use Indiana as like a as a as an example for why I think the most profound changes are going to be seen and felt in how states change up their uh regulatory regimes because Indiana's been kind of at this off and on, but with a very concentrated, it's been off and on for the last like three years, but really aggressively for in the last year or so and reworking how they over oversee ABA benefits.
SPEAKER_03So some of the things that they've implemented is a looming standard to make sure that all of the ABA providers that are a part of the Medicaid program are accredited. They've changed this was a early, this was a profound change, but this was a couple years ago. They previously would simply pay for 40% of billings. So you could work up a bill, no matter what it was. And even though on paper there might have been provisions where they they would put some level of review on that, but in practice, they just paid 40% of whatever you build. That led to a lot of the absolutely wild growth that we've seen in Medicaid spending in companies that are have headquarters or that have significant operations in Indiana.
SPEAKER_03That changed, and I want to say that went into effect in about 2024, where they just went to a fixed fee rate. Here's the fee rate for our you know 971 codes, right?
SPEAKER_00Oh, so when you say 40%, I could have billed$10,000 an hour and they would have paid 40% of that.
SPEAKER_03You're 100% correct.
SPEAKER_00Wow. Okay, go ahead.
SPEAKER_03So no, that's all good. So on so those kind of changes, another significant change that I would highlight there is that they have rolled out hourly lifetime caps on ABA. They've also tried to make this differentiation between hours and programming when it comes to uh intensive ABA. Uh they're trying to make some kind of distinction between kids that are getting, you know, your very high intensity 40 hours a week as opposed to kids that are getting a little bit that are in a little bit lower regime. And like some if you're not in a heavy hour a week program, like your caps would be a little bit different.
SPEAKER_03So the states have gone from like not really understanding not really understanding ABA generally and being frankly a little bit too permissive with it as a benefit, to being very, very strict and being very and being so prescriptive as to actually step in and say, these are how many hours we want you to show that you, as an operation, st uh comport with these third-party standards. And it can probably be summed up as a very, very painful but very fast maturation that no other segment of healthcare has probably undergone this in recent memory, right?
SPEAKER_03I'm trying to think of corollaries and like you know, maybe there's a home health industry where it was kind of obscure, but then it grew really, really quickly, and then there was a lot of painful upgrades and changes, and that happened over the course of like maybe 10-15 years. We're seeing a lot of this play out in like three.
SPEAKER_00Wow, that's wow, that's really I mean, the pendulum all with everything, right? It sounds like the pendulum kind of swings one way, so it was really open and kind of like a free-for-all, and then as an overcorrection, now it's a little bit more restricted. And I mean, I can't help but look at, I'm sure that a lot of ABA providers had uh took advantage of that that system. And it's not like there's no culpability in the ABA industry as well, from some of the things that I hear. You know, even when we're working with insurances, you know, I hate to say this, but I've been surprised it it's been pretty, pretty easy on on our end, at least on the clinical side of things.
SPEAKER_00And I hate to say this, but a lot of times I kind of see where they're coming from because, like you're saying, the hours caps and and things like that. So so I can see where that comes from. And I don't think, you know, I think a lot of times in our field, and like we talked about before we came on, there's a really interesting kind of almost societal thing where people have to pick a pick one side, and that's that's what we're gonna do. It's like ABA's great, and that's we just, you know, we need to do what we're doing. And then the other side is, you know, ABA is terrible, and all they do is overbill. And it's like you have to pick a side, which one are you on?
SPEAKER_00Insurance companies are good or they're bad. It's like, well, maybe there's some some middle ground there. And what you said made me think about that, that 40% that that was there for a lot of providers. And overutilizing that, it probably if it wasn't overutilized, would have never been never been thought of. But you know, the overutilization of that brought on by ourselves now made people look at it. And now, because there probably wasn't strict guidelines, led somebody to say, well, if they can't cover themselves, somebody needs to cover them.
SPEAKER_00We've got to come up with some sort of guidelines, which then on the flip side can lead to like overstringencies, right? Of like people coming in that don't know the case. And like, you know, I I've heard Mike talk about this a lot with our cases where we have insurance reviewers and knock on wood again. We haven't had many at our company deal with this, but they're kind of prescribing how many hours that you can do, but we're the experts. But they tried to let the experts do it, and maybe they ran too much of it. So that was kind of a lot of words salad there.
SPEAKER_00I don't know if you want to make any uh sense of that for our listeners or add some thoughts to that, Chris.
SPEAKER_03But I do want to jump in and you know, you know, Dan, I totally hear where you're coming from, where and you're showing a lot of you know you know open-mindedness and maturity and acknowledging that yeah, you know, your fraud is real, overbilling is real, things like that are real. But I want to go, I want to go out of my way and actually stand up for the industry a little bit. I don't think this is anywhere close to the norm. So if anybody is wanting to do any broad brush painting, it is frankly unfair and inaccurate to say like this is an industry that's like riven with fraud. There's a huge difference between sloppy billing, not having the right signatures on the right forms, not attaching the plan that was part of the prior auth, but it needs to also need to be part of the claim.
SPEAKER_03That's just that's that's frankly, that's that sloppy work, it's not fraud. There's a huge difference between just not being good at billing and doing things that aren't compliant with like billing rules, and then going out of your way to defraud a system. I want to point something out that I picked up over the last couple of years of observing federal actions and state actions when it comes to fraudsters. What a lot of the bad practices that we do see and that are showing up in like your federal OIG reports are not fraud. It's just bad billing. And if it's bad billing and it's not compliant, it shouldn't be paid.
SPEAKER_03That's the rules. But that is not at all what fraudsters do. Fraudsters will go out of their way to make congo out of their way to make concealing actions, not even bother to like you know, provide services, we'll use some kind of sketchy method to try to get like Medicaid numbers and things like that. We see that a we see that a lot in like other kind of obscure segments of healthcare, but in all of the recent actions that we've seen in the federal government, there have been a lot more recently. The greater majority of those have been in more generalized mental health and behavioral health and maybe addiction treatment services.
SPEAKER_03We're not seeing a lot of this in autism therapy. Now, the stuff that we're seeing out of Minnesota, that's bad, but it's a Minnesota problem. It's not a Pennsylvania problem yet. I mean, I'm sure something will probably happen that'll prove me completely wrong, or it's not a Utah problem yet. Like again, something will probably happen in Utah that'll prove that I'm that that I was completely wrong about that. But to ever consider and conceptualize this industry as one that's driven by fraud is frankly unfair and inaccurate. And I will also observe that a lot of people that make this argument, they also fail to prove the point.
SPEAKER_03They also fail to like give me a substantive number, like, well, how much of this industry is genuinely fraud and not just bad billing? And no one can ever no one can come up with a number. I can come up with a number about like how much you know billing over the course of a certain number of years in Indiana Medicaid is probably shouldn't have been paid, but that's not because it was proven to be fraud. It was because it was just wasn't compliant with billing rules, or like one of the things that is a really damning outcome from the series of OIG reports that we've had, and we've had several, is that a lot of the documentation for these claims is so bad that you really can't determine like what happened like in the claim or like if it actually met a certain level of care standard that you know assessors can use as a kind of a baseline for when they're looking at who's doing a good job, who maybe needs to like be looked at a little bit more closely.
SPEAKER_03So even if you were a good provider, you just happen to not have a great system, you're you know, you're still gonna get lumped into this wider concept that Dan articulated about either you're good or you're bad, and you're gonna be articulated as bad, even though you just might not happen to be a great billing.
SPEAKER_00That's such a good point because like the difference between billing, bad billing, and fraud. And I can speak to that because I do the billing for for our company, and that is a nightmare. And you have to have specific people, and we have to have expensive platforms to be able to do that to meet the criterion and on the margins that it's it's tricky, and that's you know, that that'll be something that we can we can go down that that realm a little bit later. But uh there's also an interesting flip side to that too, that I've had plenty of correct billing, and I deal with this often, that gets denied, and now I have to go out of my way and call, and they're like, oh yeah, we're you know, it takes whatever, 30 days to reimburse.
SPEAKER_00I have to find the error. I have to call them and they're like, Oh yeah, we actually should have paid that. And then it's another 30 days for them to reprocess the claim. So there's not only is there bad billing, but there's also bad paying on the other side of things as well. So it's kind of a double, you know, sided street. I did have one question I wanted to follow up and then I'll pass it back to you, Mike, kind of on what we were talking about with the Medicaid Medicare piece. So we're in California and the majority of our current clientele is actually funded by private insurances.
SPEAKER_00So you had something that I thought was really enlightening because some people might be listening to this and be like, well, the Medicaid and the Medicare kind of stuff that might affect other providers. I have a lot of buddies that work on the East Coast, South Carolina, Georgia, and most of their funding is Medicaid. Kentucky is Medicaid and Medicare. So that might directly affect them. But other people might have more private insurance funding and might be like, well, that doesn't affect me as much. But from what you're saying, is that a lot of the private insurance is deriving their procedures and protocols from the Medicaid.
SPEAKER_00So can you speak on how that might affect the private insurance reimbursement model as well?
SPEAKER_03Yeah, yeah. And just as a general truth, and this has been true for my observations of the entire healthcare industry, including hospitals, uh, you know, you know, nursing homes, dental practices. All private healthcare insurers are looking at Medicare and Medicaid as a baseline or as a kind of, like I said, pace setting car for like what their rates look like, what their practices look like. Because ultimately, those federal plans, even though they are independent from the government, they are regulated by the government. Again, going back to the centrality and the power of the federal government.
SPEAKER_03So it's a really easy kind of short pat shortcut on how to originate how you're doing your benefits, what your procedures are going to look like, how much you're going to pay is going to look like by using the benchmark that Estate Medicaid program sets or what the federal government sets for a certain code. So even if one does not actually take, you know, have a Medicaid contract or work with, you know, a local entity like a local healthcare authority, they they're going to be impacted because those pe those entities are coming at this with way more authority than any other member of the healthcare in the healthcare marketplace.
SPEAKER_03They're the ones building the marketplace and determining who can shop at the marketplace, what you can sell at the marketplace. They're not just another health plan.
SPEAKER_00And I think one example that I can think of specifically is we've run into with our 97151, the assessment authorizations. Any code has an MEU, like amount of hours that we can bill per day. And we've fought with some insurances, and they're all of every private insurance that we work with either references the Medicaid E MEU or the Medicare E MEU. So that's kind of guiding their provision of how much they'll bill. So yeah, that goes to the the government's kind of regulations and and procedures as well.
SPEAKER_00Uh Mike, I know I've I've hogged a lot and I got a lot more to ask, but let me pass it back to you, brother.
SPEAKER_01The only difficulty I'm having today is which question to ask first based on what we're talking about. And so thank you for that, Mr. Larson. Do you uh I guess one of the things I was thinking about as you guys were talking, do we make ourselves easy targets in a sense to the question or the premise of of fraud? Does how does that affect, would you, you know, provide some conjecture on our rates, for example, that we get with private insurance? So the idea that I've always looked at ABA a little bit like maybe diabetes treatment, like some of you that that's going to be sort of on and off, self-monitored or uh monitored throughout your life in some way.
SPEAKER_01And that, you know, diabetes treatments often used as a healthcare model to examine cost over a lifetime. It's a it's a nice strong model that's well researched. How easy of a target, especially as new guys to the table, do we make ourselves when we make so-called empirically validated recommendations for standard 30 hours a week? So now not only are we long-term treatment and many in the eyes of many providers, and we're expensive, and now we're intensive.
SPEAKER_01And and we don't have good, I mean, I'll say, I'll be the first to say, we're trying to figure out good answers to when do you terminate, when do you exit a patient or a client. These are all, as new guys, these are all questions we're contending with. So all those things taken together, I mean, we do we make ourselves pretty easy targets for this one incident of fraud, and then now that one incident, you know, the the the old adage, the the apple in the barrel, right? We have that one incident, doesn't have to happen a whole lot, but it happened there, and then now we're back on on the uh chopping block, or we're back in the hot seat.
SPEAKER_03I would say that that it that premise in that arrangement is as true as I am bald. Like you can't like I I like where I really like the idea of trying to frame up and understanding ABA within the context of diabetes and long-term treatment, but it gives us a really helpful contrast to what healthcare can and has proven it can understand, it can process, and what it can't.
SPEAKER_01There you go.
SPEAKER_03There are multiple there are multiple pills and therapies that have a really strong track record in the mitigation of symptoms that are related to diabetes. There is not there's there's not a medication that actually does really address truly, you know, the core the core deficits that are defined in you know your d in the DSM that are related to autism. There is only really two true manifestations that we articulate really at most when it comes to diabetes. Autism is a spectrum that is widely defined, is widely experienced.
SPEAKER_03And the there while there are like concurrent, there are currently like there are many attempts to try to phenotype it, the infinity, the infinity of manifestations and experiences cannot be tolerated by a system that is very compartmentalized and focused on things that can be observed and then influenced in a medical, but also in kind of an academic and like clinical and uh like laboratory model. So there is no more strange or different or incompatible practice to the healthcare model than ABA that does all the things that you talked about, Mike.
SPEAKER_03High intensity, long-term, and because of that, the high cost. It's all all love to uh when I had here was it was more blondie, but like uh my beard, my beard is red, but all love to redheaded stepchildren everywhere. Uh, it wouldn't be unfair to describe ABA as kind of the redheaded stepchild in the healthcare family. Nobody kind of knows what to do with it and to its detriment.
SPEAKER_01Newly adopted. I mean, we can go on with that metaphor, go on and on. Go on and on with that one for sure. So kind of going back to the idea of federal government, just to revisit that, uh, interesting. I mean, so what where where is the where are the blinders here? Maybe it's just political, maybe it's more financial, but knowing that uh so the the incidence rate, that that's a concern, you know. We can be honest about that. Wow, this thing cost a lot. Wow, one in 31 or however more we want to inflate that based on what source we're looking at, and we can spend some time looking about that because I'm sure you know a little bit about that.
SPEAKER_01But yeah, clearly that can be a cause for alarm. And then there's everything else we know. Super general question where is that gap? Does do we have a do we have a hope to fill that gap to educate people on that? I mean, that there's a lot to be said there. So the idea that uh, you know, Jay Bodhicharya, that's a that's a respectable dude now leading the NIH, but for him to now be behind this same political movement, which maybe without mentioning us so specifically, still puts us on some sort of chopping block.
SPEAKER_01But the the notion to then come out and say, we're we're doing this research because now this decades-old body of research that has been rigorous and it's out there, somehow we're discounting all that, right? So, I mean that there's a lot of impact to these these political notions, these premises that come out. Yeah, where how do we feel that? Is it is it something that that is is again gonna have this huge impact, or does it go away in four years because now we're back to the more academically driven UC Davis Mind Institute, you know, however many other institutes we want to mention, with with many, many experienced researchers who have been at this question for so long, clearly an important question, speaks to the incidence rate, which seems inflated and concerning, but could be explained, yet there's so many gaps to fill in political or policy or otherwise public knowledge on that.
SPEAKER_01I threw a lot at you. I know you can unpack it.
SPEAKER_03So from it when we're talking about like when we're talking about more cultural things, when it comes to the perception of autism and then the pers the neighboring perception of those that do what they can to help people live their best lives who are recognized with these symptoms, that skepticism is always gonna be there. It and frankly is is is magnified but independent from whoever is in the White House right now. So, you know, you've you guys have talked about a lot, you know, the the neurodivergent affirm affirming movement that is that some portion of has gone out of its way to really push back against practices in ABA.
SPEAKER_03Sure. That's not gonna go anywhere. That's always gonna be around. And in the social media age, they have all kinds of tools and means to stay relevant, to continually organize and to grow. So to answer your question, like culturally, like there's always going to be this, there's always gonna be skepticism. Will it be at the same degree that we're experiencing today? Maybe not, maybe so. It's hard to say, but I can definitely say that there will be at least some, at least temporary, deflation because there isn't such an epic, powerful entity, i.e. the federal government, that is so skeptical towards even autism as a diagnosis.
SPEAKER_03Now, you guys are gonna know way better than me, and the academics that you guys have are gonna know way better than me that there is this head kind of head-scratching decision by the folks that put together the DSM to consolidate a lot of similar symptomology into just one diagnosis, that being autism, you know, autism inspection disorder. Was there greater utility from a clinical or from an academic and like kind of a public health perspective and having greater subtlety by being able to diagnose Asperger's syndrome as opposed to just autism?
SPEAKER_03I I don't know. I don't even have high enough degree to even approach that question. I only have a bachelor's degree. That's actually kind of a kind of a point of like chuckles amongst my staff, my fellows at uh BHB who I work with, uh, they've all got master's degree. I don't have a master's degree. So so there's there's obviously utility in trying to bring greater subtlety to any situation, but we also can't totally explain away the increasing incidence that we measure that you know the Adam program measures in eight-year-olds simply by a change in definition.
SPEAKER_03There's something going on in the collective American psyche that is lending towards these diagnoses. I don't know what they are, and I don't know to what degree destigmatization of mental health issues is is playing here. I don't know what role if any social media or screen time is playing in the development of human brains. I don't know what role if any environmental pollutants are genuinely playing in the development of brains and in the manifestation in children's behavior. That being said, I do know that because at least a potentially positive externality that's coming out of this, there is a lot of questions about the health of children that you know were never forgotten.
SPEAKER_03They just have been put in the limelight in a really special way. And if there is like kind of a positive externality that kind of comes out of the crazy moment that we're in, is maybe there will be more research and there'll be greater understandings about how the world around us impacts the health and the development of growing brains. And again, that that's not like a great answer to your question, Mike, if I'm being completely honest. And there's not really not much else, you know, I can say because a lot, a lot of answering that is going to come down to the public health experts and then the experts you know that are doing the academic research that answer those questions on like what is this really, what causes it?
SPEAKER_03And if there is a genuine utility in understanding the cause when it comes to applying that to treatment, we'll find that eventually. But I don't think the universe the universe that we live in really knows how to even approach those questions just yet.
SPEAKER_01Well, I I appreciate your very conscientious answer. I know that was outside of the scope of business per se, but I I figured you'd have something to say about it. So I I I I do appreciate that. Mr. Dan?
SPEAKER_00I I really uh I was just marinating on. What you talked about, you know, the the different phenotypes of autism. And is there sometimes benefit of going down a little bit more so that the treatment can be prescriptive? And I was just kind of marinating on that a little bit, because you talked before you came in about maybe wanting to get into the cardiothoracic doctor realm. And I actually had thoracic outlet syndrome and I had surgery for it. And you know, with a lot of medical stuff, it's like super specific, right? Like I had thoracic outlet syndrome, venial type.
SPEAKER_00Like so it's very specific. And because that you can have that level of specificity, you can have a specific treatment that works or a couple treatments that work for that. But it's not like, well, I had a heart issue. Like that's super broad. And it almost seems like, you know, you just got me thinking of that's kind of like what autism is is like somebody has a heart issue, and it's like, well, okay, but like we're now trying to prescribe one procedure for all heart issues, and there's so much variability between how people with autism or autism spectrum disorder present that that is pretty challenging, I imagine, for you know, somebody in the the medical insurance or medical reimbursement billing, because that's not typically how they uh how they operate, I would assume.
SPEAKER_00And that you just got me thinking about that. So that I I find that very interesting.
SPEAKER_03Yeah, and to throw in a little, like a little like more kind of positive outlet on that one, you know, this one I do have a little bit of like lived experience with is that I was very diagnosed very young with ADHD. Not surprisingly, my son diagnosed with ADHD as well. But in that diagnosis, you have the diagnosis, but then you also have uh you have at least what I'm aware of, and of course, you know, all the uh you know, the actual psychologists and psychology expert circuits are going to be absolutely ashamed of me for not knowing the splitting subtlety, but in that manifestation, you get inattentive, hyperactive combination.
SPEAKER_03And at least in in this other, you know, like kind of maybe second cousin to you know autism in terms of diagnostics, there's at least enough subtlety there to recognize that yes, there is a common brain, you know, brain issue that's manifesting in certain behaviors, but here's enough subtlety that we can tweak approaches to making sure that symptomology is ameliorated to the degree that it can be so that they can live a good life.
SPEAKER_00Yeah. That's and you know what that gets me thinking, Mike. Let me pass it to you to explain because you can explain it better than I do when we're talking about like ADHD or any of these diagnoses, diagnostic substitution. I know that's been something that you've kind of explored for a little bit. Is that something that you think would be relevant to interject into this discussion?
SPEAKER_01Well, when we're talking about incidence rate, that's one of the things that I think explains the concern in that increase, right? So the idea that to use the ADHD question or or or premise, there's there's a known medical treatment for that. You can get medication for that. The ABA or behavioral approach to that would, as far as I know, isn't covered by anybody yet. Maybe there's examples out there, I think Down syndrome, uh, maybe some medical providers are now covering for that a little bit.
SPEAKER_01So I I guess I've wondered, and I don't know if you can speak to this at all, or what your interpretation of this would be, but the idea that some parents who don't want to go down the medication route might now might now seek diagnostic for something that is covered, like autism spectrum disorder, in order to get folks like us, because if you don't have autism spectrum disorder, well then you're not gonna be covered for ABA. I don't know if you've got anything to say about that premise.
SPEAKER_03So I will say I don't know. That's not something that I've come across so far in my career, but it frankly wouldn't surprise me that a parent would try to do what they can for the benefit of their child, even if it is to try to you know go for a diagnostic that looks like some of the symptoms, but otherwise wouldn't necessarily necessarily wouldn't comport with the totality of their symptoms. Yeah, on that one, on that one, I don't know, but I could see where you're coming from. I don't know what else if you were thinking about something different, Dan.
SPEAKER_00It was just as we were talking about, you know, ADHD or any of those symptoms. Sometimes the the diagnosis almost seems circular. It's like this person has these traits, and we diagnosed them with this label that says they have these traits, so it just becomes like circular. I wanted to switch gears a little bit. Did you have anything else on that one?
SPEAKER_01No, go right ahead.
SPEAKER_00Wanted to talk a little bit about uh let me actually pull up the article a little bit about private equity in ABA because that's been a big phenomenon, I guess, in the last, and you alluded to it in your introduction here in maybe the last five to seven, you know a lot more than I do. I would say five to seven years that I've seen it. And there's you know a few articles here in Stat News. One of them, Mind Path, seemed like a success story for private equity in mental health. Now it's a cautionary tale. It's actually the company that bought our company out two ago and then realized they didn't know enough about ABA or wasn't what they thought it was gonna be.
SPEAKER_00Another one, parents and clinicians say private equity's profit fixation is short-changing kids with autism. And the last one, why massive investment in autism companies created a ticking time bomb. So I'm gonna kind of open this up to you, Chris. There's a couple of different thoughts I have. Um, one is just kind of what's your thought on the general landscape. And the next question that I have is it seems like, you know, for example, MindPath, the company that bought us out, got out of the autism business. There's another company that I'm aware of that's bought a couple smaller outfits out and is like, wait, maybe this isn't as good or as profitable or as lucrative as we thought.
SPEAKER_00So, my my question is I guess more on the macro scale. What effect is it having? And also on the individual private equity scale, there's intelligent people in these, you know, companies, obviously. What's what's going on? Why are they not able to run successful ABA practices as they thought they would when they acquired them?
SPEAKER_01Just really briefly, I'm old enough to remember when the mandates, the insurance mandates were starting. So everybody in mental health was hoping to add that ABA division to their companies. And then here Dan's presenting the contrast, which is now some of these bigger mental health providers having to run away maybe because they don't know enough about what we do, didn't know what to do with us. Anyway, I'll pass it to you, Chris.
SPEAKER_03No, Mike, you're you're already like spot on with a lot of what the early era stumbles looked like. We've highlighted multiple times, and I'll go back to what I've said, is that ABA is and autism therapy generally is not really well stood, well understood within healthcare. There is a huge pipeline of executives and strategists, investors that know hospitals really well. They know dent they know dental practices really well. We don't have a comparable cohort of executives that can kind of come out of a existing tradition of how to successfully run that type of a business.
SPEAKER_03Those people are few and far between. And if you're trying to get people that have done, say, dental services, you know, roll ups before, people who have worked in like nephrology and tried to do the guys, help me out here. You get hooked up to machines because your kidneys don't work.
SPEAKER_01Dialysis?
SPEAKER_03Dialysis in the dialysis world, they don't understand and appreciate the subtleties of the industry. And if you don't understand the subtleties of a industry, you're not going to be successful. So one of the structural things because of the youth of the industry is there's no large, meaningful cohort of people that know the industry well enough to take a really great concept that can exist in a couple of cities and spread it across the country. That was part of that's part of the issue of like what I'll call kind of 1.0 or 1.5 of the companies that struggled circa 22 to 23.
SPEAKER_03Now, to get to like the wider criticism of private equity, well, why can't they get this figured out? There's also a big time come back down to earth moment that all of all of healthcare investing is experiencing right now. During COVID, interest rates were on the floor. It was unrealistic and it was always going to change, but a lot of private equity people said, hey, look, debt is practically free right now, and we can go compile you know equity from our partners who give us a whole bunch of money for us to go invest, supplement that with pretty much free debt, and go buy these companies that got a lot of money themselves.
SPEAKER_03You know, the BCBs that founded them cashed out, left, and they were left with the suits that try to try to run these organizations. They didn't know how to do it. So when either co when when COVID started to pull back and it was time to try to get into the normal operations of things, a lot of companies struggled with how to actually operate the business because you know, frankly, ABA is not a very high high margin business because of the intensity of the service. You have to spend a ton of money paying the people just to make sure that the service happens in the first place. So there's not a ton of wiggle room for you know foibles in your expansion plan, there's not a ton of wiggle room for like some unforeseen catastrophe that happens, like you know, even if even something as like innocuous as like some like a very bad pipe issue at a clinic, you know, if you're losing all of that revenue, that's a huge hit to your bottom line, right?
SPEAKER_03So because there's not a lot of play, there's not a lot of wiggle room, there's frankly not a lot of profitability in ABA. A lot of the people, a lot of the operators did not appreciate that and thought that they could kind of brute force through that by scaling up really quickly. But when you scale up really quickly, what you do is you magnify problems that can't be resolved at the micro level to the macro level. Oh, we've we've seen that.
SPEAKER_00What we've seen, and we're seeing it not at our company, but we're seeing it from a little bit of a distance, is when you scale up, also you can become really top heavy. And these people are not bringing in any income, but they're costing. And these all of a sudden become the highest paid individuals that are not bringing in money. And then when there's ever any problems, it's never them looking at themselves, it's looking at how do we work people more? How do we lay off people that are bringing in money? And then when those people get laid off that were bringing in the money, they're wondering why there's less money coming in.
SPEAKER_00So we would definitely see it. And I mean, I almost understand it. We've got 35 clients or something like that somewhere in that ballpark with a few clinicians. And, you know, I do some of I do most of the billing, and we have some people like that. But like as you get bigger, you need billers, you need, you know, recruiting people, you need people to make sure that you're staying in compliance with all of these insurance regulations. There's like a lot of a lot of stuff that goes on and a lot of unpaid people that can start to get jobs, and the margins, like you said, aren't aren't that amazing.
SPEAKER_00And it seems like a lot of them are actually dropping as the you know, they get a little bit tighter on the the financing, and that that's definitely pretty tricky.
SPEAKER_03Yeah, and just real quick, I want a quick notion that I wanted to like double uh double click on, as they say. Sorry, that's that's a terrible bit of like corporate jargonism that's perfect. It's perfect. But to re to reiterate the point, if there's an assumption or a premise or like a theory or guiding idea that the practice of autism therapy at any time is a big money business, is diluted. It's just not true. This is not an industry that is again absolutely just flooded and glutted with cash. It's not, and frankly, organizations that are in autism therapy are never going to be able to carry a ton of cash because of one, because the margins aren't great, but two, because ABA has always kind of been awkwardly handled, there's huge delays in getting paid.
SPEAKER_03And that's actually one of the reasons why private equity kind of came into the space because they thought, well, we know we know numbers, we know billing, we know systems, we know technology. We might not know clinical stuff, but we do this every day, all the time in every industry. So they saw an industry that had a lot of operational problems that you know, we're the suits, we know how to fix that stuff. To some degree, they kind of did, because they're for every company that you can point to that is falling apart, I'll show you one that's operating just fine. And then probably make that that ratio for every one company that's falling apart, I'll show you two or three that are either getting by or doing well.
SPEAKER_03And that's because of the maturation that the private equity industry brought in to take this from uh you know a husband and wife, where you know, one of the two is doing most of the clinical work, the other person's up till midnight in the basement trying to get the you know the documents faxed to that one payer and things like that to operations that look like they should be in the in the ball game of business. And at the end of the day, the world is as it has played out, like we can't change what the world is by reminiscing about the past.
SPEAKER_03So with that in mind, I always feel like I need to point out that the we've gotten the industry has gotten this far, it's gotten to the scale that it has, and we have seen access increase to the degree that it has because of private equity. Okay. The state governments weren't going to do this. There's amongst the clinician, the collective clinician cohort, there's nowhere near enough personal wealth and capital to get enough businesses to the size that they need to be to start meeting the demand that has been met so far today. So, you know, we can't it it's very fair to reminisce negatively about the arrival of private equity into uh ABA because the arguments I think for the most part are are pretty valid.
SPEAKER_03A lot of them are made in bad faith, I would say. But we have the access that we have, we have BCBAs making more money than they've ever made. We have more jobs for BCBAs than there are to fill them. We have people falling over themselves to try to get these BCBAs and give them crazy bonuses to try to sign on. We have people coming out of college that can make on the high end of the five figures because of the arrival and interest from a business perspective of investors in in the ABA industry. Now, again, that came along with all the challenges that we've talked about, but you know, tell show me an ABA, show me a BCBA right now that's working at kind of a commercially clinic, and I and I will show you somebody who needs to be grateful that there was enough interest and capital in the space to create a space where they could have a job.
SPEAKER_01Grateful indeed. This is a great place to stop for part one of our invigorating interview with Chris Larson. Please do return for part two and always analyze responsibly.
SPEAKER_02ABA on TAP is recorded live and unfiltered. We're done for today. You don't have to go home, but you can't stay here. See you next time.
Send us Fan Mail ABA on Tap is proud to present Richard Wagner (Part 2 of 2): One tiny checkbox can be the difference between a clean claim and a full-blown payer denial, and most ABA clinicians only find out after the...
Send us Fan Mail ABA on Tap is proud to present Richard Wagner (Part 1 of 2): If your ABA tech stack feels like it was built for billers instead of clinicians, youโre not imagining it. ABA onTap sits down to brew with...
Send us Fan Mail ABA on Tap is proud to present CartNarcs Special Agent Sebastian Davis (Part 2 of 2): A stray shopping cart is never just a cart. Itโs a tiny decision with outsized ripple effects, and it can tell you a...
Send us Fan Mail ABA on Tap is proud to present CartNarcs Special Agent Sebastian Davis (Part 1 of 2): A stray shopping cart can scratch paint, block a space, and ruin somebodyโs day, but the bigger story is what...
Send us Fan Mail ABA on Tap continues the brew with Holly Blais (Part 2 of 2): A school can be loud with โproblemsโ and still be full of useful information, if you know how to listen. ABA on Tap resumes their chat with...